Selected research
Industry Research
Intramuscular Injection of Pain Medication Industry Research Report 2026
Market perspective
The global Intramuscular Injection of Pain Medication market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Intramuscular Injection of Pain Medication market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Intramuscular Injection of Pain Medication market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Intramuscular Injection of Pain Medication market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Intramuscular Injection of Pain Medication include Yangtze River Pharmaceutical Group (YRPG), Shijiazhuang Pharmaceutical Group, Sanofi, Humanwell Healthcare, Qilu Pharmaceutical, Novartis, Merck, Roche and Pfizer, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Intramuscular Injection of Pain Medication market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Intramuscular Injection of Pain Medication.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Intramuscular Injection of Pain Medication Market by Company
Yangtze River Pharmaceutical Group (YRPG)
Shijiazhuang Pharmaceutical Group
Sanofi
Humanwell Healthcare
Qilu Pharmaceutical
Novartis
Merck
Roche
Pfizer
China Resources Double Crane
Hengrui Medicine
Sinopharm Group
Fresenius Kabi
Northeast Pharmaceuticals
AstraZeneca
Hikma Pharmaceuticals
Grünenthal
Intramuscular Injection of Pain Medication Segment by Type
Opioid Analgesics (Opioids)
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Local Anesthetics
Others
Intramuscular Injection of Pain Medication Segment by Application
Hospital
Clinic
Others
Intramuscular Injection of Pain Medication Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intramuscular Injection of Pain Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Intramuscular Injection of Pain Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intramuscular Injection of Pain Medication.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Intramuscular Injection of Pain Medication companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Opioid Analgesics (Opioids)
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Local Anesthetics
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Yangtze River Pharmaceutical Group (YRPG)
- Shijiazhuang Pharmaceutical Group
- Sanofi
- Humanwell Healthcare
- Qilu Pharmaceutical
- Novartis
- Merck
- Roche
- Pfizer
- China Resources Double Crane
- Hengrui Medicine
- Sinopharm Group
- Fresenius Kabi
- Northeast Pharmaceuticals
- AstraZeneca
- Hikma Pharmaceuticals
- Grünenthal
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Intramuscular Injection of Pain Medication by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Opioid Analgesics (Opioids)
- 2.2.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 2.2.4 Local Anesthetics
- 2.2.5 Others
- 2.3 Intramuscular Injection of Pain Medication by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Intramuscular Injection of Pain Medication Breakdown Data by Type
- 3.1 Global Intramuscular Injection of Pain Medication Historic Market Size by Type (2021-2026)
- 3.2 Global Intramuscular Injection of Pain Medication Forecasted Market Size by Type (2027-2032)
4 Intramuscular Injection of Pain Medication Breakdown Data by Application
- 4.1 Global Intramuscular Injection of Pain Medication Historic Market Size by Application (2021-2026)
- 4.2 Global Intramuscular Injection of Pain Medication Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Intramuscular Injection of Pain Medication Market Perspective (2021-2032)
- 5.2 Global Intramuscular Injection of Pain Medication Growth Trends by Region
- 5.2.1 Global Intramuscular Injection of Pain Medication Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Intramuscular Injection of Pain Medication Historic Market Size by Region (2021-2026)
- 5.2.3 Intramuscular Injection of Pain Medication Forecasted Market Size by Region (2027-2032)
- 5.3 Intramuscular Injection of Pain Medication Market Dynamics
- 5.3.1 Intramuscular Injection of Pain Medication Industry Trends
- 5.3.2 Intramuscular Injection of Pain Medication Market Drivers
- 5.3.3 Intramuscular Injection of Pain Medication Market Challenges
- 5.3.4 Intramuscular Injection of Pain Medication Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Intramuscular Injection of Pain Medication Players by Revenue
- 6.1.1 Global Top Intramuscular Injection of Pain Medication Players by Revenue (2021-2026)
- 6.1.2 Global Intramuscular Injection of Pain Medication Revenue Market Share by Players (2021-2026)
- 6.2 Global Intramuscular Injection of Pain Medication Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Intramuscular Injection of Pain Medication Head Office and Area Served
- 6.4 Global Intramuscular Injection of Pain Medication Players, Product Type & Application
- 6.5 Global Intramuscular Injection of Pain Medication Manufacturers Established Date
- 6.6 Global Intramuscular Injection of Pain Medication Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Intramuscular Injection of Pain Medication Market Size (2021-2032)
- 7.2 North America Intramuscular Injection of Pain Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Intramuscular Injection of Pain Medication Market Size by Country (2021-2026)
- 7.4 North America Intramuscular Injection of Pain Medication Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Intramuscular Injection of Pain Medication Market Size (2021-2032)
- 8.2 Europe Intramuscular Injection of Pain Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Intramuscular Injection of Pain Medication Market Size by Country (2021-2026)
- 8.4 Europe Intramuscular Injection of Pain Medication Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Intramuscular Injection of Pain Medication Market Size (2021-2032)
- 9.2 Asia-Pacific Intramuscular Injection of Pain Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Intramuscular Injection of Pain Medication Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Intramuscular Injection of Pain Medication Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Intramuscular Injection of Pain Medication Market Size (2021-2032)
- 10.2 South America Intramuscular Injection of Pain Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Intramuscular Injection of Pain Medication Market Size by Country (2021-2026)
- 10.4 South America Intramuscular Injection of Pain Medication Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Intramuscular Injection of Pain Medication Market Size (2021-2032)
- 11.2 Middle East & Africa Intramuscular Injection of Pain Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Intramuscular Injection of Pain Medication Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Intramuscular Injection of Pain Medication Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Yangtze River Pharmaceutical Group (YRPG)
- 12.1.1 Yangtze River Pharmaceutical Group (YRPG) Company Information
- 12.1.2 Yangtze River Pharmaceutical Group (YRPG) Business Overview
- 12.1.3 Yangtze River Pharmaceutical Group (YRPG) Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.1.4 Yangtze River Pharmaceutical Group (YRPG) Intramuscular Injection of Pain Medication Product Portfolio
- 12.1.5 Yangtze River Pharmaceutical Group (YRPG) Recent Developments
- 12.2 Shijiazhuang Pharmaceutical Group
- 12.2.1 Shijiazhuang Pharmaceutical Group Company Information
- 12.2.2 Shijiazhuang Pharmaceutical Group Business Overview
- 12.2.3 Shijiazhuang Pharmaceutical Group Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.2.4 Shijiazhuang Pharmaceutical Group Intramuscular Injection of Pain Medication Product Portfolio
- 12.2.5 Shijiazhuang Pharmaceutical Group Recent Developments
- 12.3 Sanofi
- 12.3.1 Sanofi Company Information
- 12.3.2 Sanofi Business Overview
- 12.3.3 Sanofi Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.3.4 Sanofi Intramuscular Injection of Pain Medication Product Portfolio
- 12.3.5 Sanofi Recent Developments
- 12.4 Humanwell Healthcare
- 12.4.1 Humanwell Healthcare Company Information
- 12.4.2 Humanwell Healthcare Business Overview
- 12.4.3 Humanwell Healthcare Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.4.4 Humanwell Healthcare Intramuscular Injection of Pain Medication Product Portfolio
- 12.4.5 Humanwell Healthcare Recent Developments
- 12.5 Qilu Pharmaceutical
- 12.5.1 Qilu Pharmaceutical Company Information
- 12.5.2 Qilu Pharmaceutical Business Overview
- 12.5.3 Qilu Pharmaceutical Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.5.4 Qilu Pharmaceutical Intramuscular Injection of Pain Medication Product Portfolio
- 12.5.5 Qilu Pharmaceutical Recent Developments
- 12.6 Novartis
- 12.6.1 Novartis Company Information
- 12.6.2 Novartis Business Overview
- 12.6.3 Novartis Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.6.4 Novartis Intramuscular Injection of Pain Medication Product Portfolio
- 12.6.5 Novartis Recent Developments
- 12.7 Merck
- 12.7.1 Merck Company Information
- 12.7.2 Merck Business Overview
- 12.7.3 Merck Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.7.4 Merck Intramuscular Injection of Pain Medication Product Portfolio
- 12.7.5 Merck Recent Developments
- 12.8 Roche
- 12.8.1 Roche Company Information
- 12.8.2 Roche Business Overview
- 12.8.3 Roche Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.8.4 Roche Intramuscular Injection of Pain Medication Product Portfolio
- 12.8.5 Roche Recent Developments
- 12.9 Pfizer
- 12.9.1 Pfizer Company Information
- 12.9.2 Pfizer Business Overview
- 12.9.3 Pfizer Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.9.4 Pfizer Intramuscular Injection of Pain Medication Product Portfolio
- 12.9.5 Pfizer Recent Developments
- 12.10 China Resources Double Crane
- 12.10.1 China Resources Double Crane Company Information
- 12.10.2 China Resources Double Crane Business Overview
- 12.10.3 China Resources Double Crane Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.10.4 China Resources Double Crane Intramuscular Injection of Pain Medication Product Portfolio
- 12.10.5 China Resources Double Crane Recent Developments
- 12.11 Hengrui Medicine
- 12.11.1 Hengrui Medicine Company Information
- 12.11.2 Hengrui Medicine Business Overview
- 12.11.3 Hengrui Medicine Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.11.4 Hengrui Medicine Intramuscular Injection of Pain Medication Product Portfolio
- 12.11.5 Hengrui Medicine Recent Developments
- 12.12 Sinopharm Group
- 12.12.1 Sinopharm Group Company Information
- 12.12.2 Sinopharm Group Business Overview
- 12.12.3 Sinopharm Group Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.12.4 Sinopharm Group Intramuscular Injection of Pain Medication Product Portfolio
- 12.12.5 Sinopharm Group Recent Developments
- 12.13 Fresenius Kabi
- 12.13.1 Fresenius Kabi Company Information
- 12.13.2 Fresenius Kabi Business Overview
- 12.13.3 Fresenius Kabi Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.13.4 Fresenius Kabi Intramuscular Injection of Pain Medication Product Portfolio
- 12.13.5 Fresenius Kabi Recent Developments
- 12.14 Northeast Pharmaceuticals
- 12.14.1 Northeast Pharmaceuticals Company Information
- 12.14.2 Northeast Pharmaceuticals Business Overview
- 12.14.3 Northeast Pharmaceuticals Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.14.4 Northeast Pharmaceuticals Intramuscular Injection of Pain Medication Product Portfolio
- 12.14.5 Northeast Pharmaceuticals Recent Developments
- 12.15 AstraZeneca
- 12.15.1 AstraZeneca Company Information
- 12.15.2 AstraZeneca Business Overview
- 12.15.3 AstraZeneca Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.15.4 AstraZeneca Intramuscular Injection of Pain Medication Product Portfolio
- 12.15.5 AstraZeneca Recent Developments
- 12.16 Hikma Pharmaceuticals
- 12.16.1 Hikma Pharmaceuticals Company Information
- 12.16.2 Hikma Pharmaceuticals Business Overview
- 12.16.3 Hikma Pharmaceuticals Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.16.4 Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Product Portfolio
- 12.16.5 Hikma Pharmaceuticals Recent Developments
- 12.17 Grünenthal
- 12.17.1 Grünenthal Company Information
- 12.17.2 Grünenthal Business Overview
- 12.17.3 Grünenthal Revenue in Intramuscular Injection of Pain Medication Business (2021-2026)
- 12.17.4 Grünenthal Intramuscular Injection of Pain Medication Product Portfolio
- 12.17.5 Grünenthal Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst